Business Context and Reporting Period
Company: Microbot Medical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2026
Event: Regulation FD Disclosure regarding commercial progress of the LIBERTY® Endovascular Robotic System.
Key Financial Metrics
This filing is a qualitative disclosure of business developments and does not contain quantitative financial data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Commercial Traction: The Company reports strong interest from physicians and hospital executives following the Full Market Release of the LIBERTY® Endovascular Robotic System.
- New Accounts: The Company has secured accounts in key sales territories.
- Strategic Wins: Two of the newly won accounts previously participated in the Company's ACCESS-PVI pivotal clinical trial.
- Catalyst: These developments were highlighted at the recent Society of Interventional Radiology (SIR) annual meeting.
Guidance, Outlook, and Risks
Outlook: Management commentary indicates positive market reception and successful conversion of clinical trial participants into commercial customers.
Risks and Contingencies: The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not deemed an admission as to the materiality of the information. No specific financial risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the specific number of accounts won and the geographic distribution of these sales territories.
- Confirm the revenue recognition timeline for the newly secured accounts.
- Review the full text of the press release (Exhibit 99.1) for additional details on the SIR meeting outcomes.
- Assess the impact of these wins on the Company's overall commercialization strategy and cash burn rate.